Trump Tax Cuts May Spark Merger Resurgence in Biotech, Drugs


Wall Street is holding its breath for the rekindling of mergers and acquisitions across the biotechnology and pharmaceutical sector after 2017 led to a pause in deal-making. Tax reform, particularly a lower levy on U.S. companies' overseas cash, may be the key to driving the return of M&A in 2018.



from Biotech News